These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27451408)

  • 1. Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.
    Kulkarni P; Korzekwa K; Nagar S
    J Pharmacol Exp Ther; 2016 Oct; 359(1):26-36. PubMed ID: 27451408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hybrid model to evaluate the impact of active uptake transport on hepatic distribution of atorvastatin in rats.
    Kulkarni P; Korzekwa K; Nagar S
    Xenobiotica; 2020 May; 50(5):536-544. PubMed ID: 31530243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple transporters affect the disposition of atorvastatin and its two active hydroxy metabolites: application of in vitro and ex situ systems.
    Lau YY; Okochi H; Huang Y; Benet LZ
    J Pharmacol Exp Ther; 2006 Feb; 316(2):762-71. PubMed ID: 16258024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Analysis of the Transporter-Mediated Drug-Drug Interaction Between Atorvastatin and Rifampicin Using a Stable Isotope-IV Method.
    Yamashita S; Hasegawa T; Tachihara M; Minami K; Higashino H; Togashi K; Mutaguchi K; Kataoka M
    J Pharm Sci; 2017 Sep; 106(9):2671-2677. PubMed ID: 28457720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys.
    Morse BL; MacGuire JG; Marino AM; Zhao Y; Fox M; Zhang Y; Shen H; Griffith Humphreys W; Marathe P; Lai Y
    AAPS J; 2017 Nov; 19(6):1878-1889. PubMed ID: 29019117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific Inhibition of the Distribution of Lobeglitazone to the Liver by Atorvastatin in Rats: Evidence for a Rat Organic Anion Transporting Polypeptide 1B2-Mediated Interaction in Hepatic Transport.
    Yim CS; Jeong YS; Lee SY; Pyeon W; Ryu HM; Lee JH; Lee KR; Maeng HJ; Chung SJ
    Drug Metab Dispos; 2017 Mar; 45(3):246-259. PubMed ID: 28069721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport is not rate-limiting in morphine glucuronidation in the single-pass perfused rat liver preparation.
    Doherty MM; Poon K; Tsang C; Pang KS
    J Pharmacol Exp Ther; 2006 May; 317(2):890-900. PubMed ID: 16464965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous Assessment In Vitro of Transporter and Metabolic Processes in Hepatic Drug Clearance: Use of a Media Loss Approach.
    Harrison J; De Bruyn T; Darwich AS; Houston JB
    Drug Metab Dispos; 2018 Apr; 46(4):405-414. PubMed ID: 29439129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Models to predict unbound intracellular drug concentrations in the presence of transporters.
    Korzekwa KR; Nagar S; Tucker J; Weiskircher EA; Bhoopathy S; Hidalgo IJ
    Drug Metab Dispos; 2012 May; 40(5):865-76. PubMed ID: 22279052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elucidating the effect of final-day dosing of rifampin in induction studies on hepatic drug disposition and metabolism.
    Lam JL; Shugarts SB; Okochi H; Benet LZ
    J Pharmacol Exp Ther; 2006 Nov; 319(2):864-70. PubMed ID: 16905688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-Dose Metformin May Increase the Concentration of Atorvastatin in the Liver by Inhibition of Multidrug Resistance-Associated Protein 2.
    Shin E; Shin N; Oh JH; Lee YJ
    J Pharm Sci; 2017 Apr; 106(4):961-967. PubMed ID: 27964938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo use of the P450 inactivator 1-aminobenzotriazole in the rat: varied dosing route to elucidate gut and liver contributions to first-pass and systemic clearance.
    Strelevitz TJ; Foti RS; Fisher MB
    J Pharm Sci; 2006 Jun; 95(6):1334-41. PubMed ID: 16625658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model.
    Ménochet K; Kenworthy KE; Houston JB; Galetin A
    J Pharmacol Exp Ther; 2012 Apr; 341(1):2-15. PubMed ID: 22190645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Altered Bile Acid Disposition Due to Inhibition of Multiple Transporters: An Integrated Approach Using Sandwich-Cultured Hepatocytes, Mechanistic Modeling, and Simulation.
    Guo C; Yang K; Brouwer KR; St Claire RL; Brouwer KL
    J Pharmacol Exp Ther; 2016 Aug; 358(2):324-33. PubMed ID: 27233294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes.
    Paine SW; Parker AJ; Gardiner P; Webborn PJ; Riley RJ
    Drug Metab Dispos; 2008 Jul; 36(7):1365-74. PubMed ID: 18426955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding the Interplay Between Uptake and Efflux Transporters Within In Vitro Systems in Defining Hepatocellular Drug Concentrations.
    Cantrill C; Houston JB
    J Pharm Sci; 2017 Sep; 106(9):2815-2825. PubMed ID: 28478131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic disposition of the acyl glucuronide1-O-gemfibrozil-beta-D-glucuronide: effects of dibromosulfophthalein on membrane transport and aglycone formation.
    Sabordo L; Sallustio BC; Evans AM; Nation RL
    J Pharmacol Exp Ther; 1999 Feb; 288(2):414-20. PubMed ID: 9918540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting metabolic clearance for drugs that are actively transported into hepatocytes: incubational binding as a consequence of in vitro hepatocyte concentration is a key factor.
    Nordell P; Svanberg P; Bird J; Grime K
    Drug Metab Dispos; 2013 Apr; 41(4):836-43. PubMed ID: 23364509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.